GNCA News and Press, Genocea Biosciences Inc. From 05/19/20

CAMBRIDGE, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced it has entered into a material transfer agreement (MTA) and exclusive license option with Shion...

Seven out of eight patients treated on Part A of the study are without disease progression at one-year median follow-up ATLAS™-identified neoantigens generate broad, sustained T cell responses starting after only 4 weeks and lasting for up to 6 months after the last vaccination ...

Thinly traded nano cap Genocea Biosciences (NASDAQ: GNCA ) is up  16%  premarket on average volume on the heels of a key opinion leader (KOL) symposium yesterday focused on GEN-011, its neoantigen cell therapy that, it says, improves on the limitations of tumor-infiltrating lymph...

CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, hosted a KOL symposium today with Dr. Eric Tran, Assistant Member at the Earle A. Chiles Research Institute in ...

CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc.  (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host a KOL symposium with a live Q&A for analysts and investors to reflect on the progress of the T...

CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host a KOL symposium with a live Q&A for analysts and investors to reflect on the progress of the T ce...

Genocea Biosciences, Inc. (GNCA) Q1 2020 Earnings Conference Call April 30, 2020, 08:30 AM ET Company Participants Dan Ferry - Managing Director, LifeSci Advisors Chip Clark - President and CEO Diantha Duvall - CFO Tom Davis - Chief Medical Officer Jessica Flechtner - Chief S...

Genocea Biosciences (NASDAQ: GNCA ): Q1 GAAP EPS of -$0.46 misses by $0.11 . More news on: Genocea Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Clinical stage programs GEN-009 and GEN-011 continue to advance Anticipate GEN-011 IND filing in Q2 Expect GEN-009 Phase 1/2a Part B readout in Q3 GEN-011 Virtual Symposium planned for May 12 th Conference call today at 8:30 a.m. EDT CAMBRIDGE, Mass., April 30, 2020...

CAMBRIDGE, Mass., April 23, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its first quarter 2020 financial results and corporate update conference call and live audio webcast ...